Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

PAREXEL Launches New Regulatory Outsourcing Service Line

Published: Friday, February 21, 2014
Last Updated: Thursday, February 20, 2014
Bookmark and Share
Company broadens portfolio of regulatory information management solutions to enhance client value.

PAREXEL International Corporation has announced the launch of a new service line designed to provide a focused, market-driven approach to regulatory outsourcing services in the life sciences industry, with a primary emphasis on post-approval regulatory activities.

Through PAREXEL Regulatory Outsourcing Services, the Company will customize these services for clients based upon their unique needs and business challenges by combining expertise, operational approaches and technology. The service line will reside within the PAREXEL Consulting business segment.

“With the ever-changing regulatory environment, pharmaceutical companies face new challenges that need to be addressed with efficiency and cost in mind,” said Mark A. Goldberg, M.D., President and Chief Operating Officer, PAREXEL.

Goldberg continued, “PAREXEL is uniquely positioned to provide this new service offering, given our regulatory expertise, global operational capabilities and information management technology. Clients will now be able to outsource significant portions of their regulatory activities to a trusted partner in a cost-effective manner.”

“Regulatory outsourcing is growing increasingly important in the market as more and more companies rely on outsourcing to help them with the complex task of managing their regulatory needs, especially the regulatory maintenance of their marketed products,” said Rick Riegel, Corporate Vice President and new head of the PAREXEL Regulatory Outsourcing Services line. “This service offering provides a unique solution that addresses new pressures felt by our clients, allowing them to become more efficient in the area of regulatory operations and affairs.”

The launch of PAREXEL Regulatory Outsourcing Services broadens PAREXEL’s portfolio of regulatory information management solutions.

In 2012, PAREXEL’s acquisition of LIQUENT, Inc. strengthened its regulatory capabilities by adding a robust information technology platform, LIQUENT InSight®.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

PAREXEL Enhances ClinPhone® RTSM Service
To simplify and expedite randomization and trial supply management for clinical studies.
Saturday, May 30, 2015
PAREXEL Announces Acquisition of ATLAS Medical Services
Acquisition strengthens PAREXEL’s presence in Turkey, the Middle East and North Africa.
Thursday, July 03, 2014
PAREXEL International Announces Acquisition of Liquent
Company acquired all of the outstanding equity securities of Liquent.
Friday, January 04, 2013
Scientific News
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
First Made-in-Singapore Cancer Drug Enters Clinical Testing
The drug prevents cancer progression and paves the way for new advancements in cancer therapeutics.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!